Drug Trial Radar · NCT06187402
A Study of LM-24C5 For Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Sep 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
49
Planned (sponsor's estimate)
Start
Dec 20, 2023
Primary completion
Jun 30, 2026
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- LaNova Medicines LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jan 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
LM-24C5Drug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs)Time frame: 60 weeks
- Incidence of dose-limiting toxicity (DLT)Time frame: 60 weeks
- Incidence of serious adverse event (SAE)Time frame: 60 weeks
- Ear TemperatureTime frame: 60 weeks
- Pulse in BPM(Beat per Minute)Time frame: 60 weeks
- Blood Pressure in mmHg (Both Systolic and Diastolic blood pressure)Time frame: 60 weeks
- Number of participants with abnormal Hematology test resultsTime frame: 60 weeks
- Number of participants with abnormal Urinalysis test resultsTime frame: 60 weeks
- Number of participants with abnormal Blood Biochemistry test resultsTime frame: 60 weeks
- Number of participants with abnormal Coagulation test results in PT(Prothrombin time), APTT(Activated partial thromboplastin time), FIB(Fibrinogen), TT(Thrombin time) and INR(International normalized ratio).Time frame: 60 weeks
- Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentageTime frame: 60 weeks
- 12-lead electrocardiogram (ECG) in RR, PR, QRS, QT, QTcF etc.Time frame: 60 weeks
- ECOG(Eastern Cooperative Oncology Group) scoreTime frame: 60 weeks
- Overall Response Rate (ORR)Time frame: 36 weeks
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
University of Southern California (USC) - Norris Comprehensive Cancer Center
Los Angeles, California · Not yet recruiting
Ocala Oncology
Ocala, Florida · Recruiting
Indiana University Melvan and Bren Simon Cancer Center
Indianapolis, Indiana · Not yet recruiting
The Christ Hospital
Cincinnati, Ohio · Not yet recruiting
Mary Crowley Cancer Research Center
Dallas, Texas · Not yet recruiting
Virginia Cancer Specialists, P.C.
Fairfax, Virginia · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.